To the G20: incentivising antibacterial research and development

Lancet Infect Dis. 2017 Aug;17(8):799-801. doi: 10.1016/S1473-3099(17)30404-8. Epub 2017 Jul 7.

Authors

Christine Årdal¹, Enrico Baraldi², Francesco Ciabuschi³, Kevin Outterson⁴, John H Rex⁵, Laura J V Piddock⁶, David Findlay⁷; DRIVE-AB Steering Committee

Affiliations

¹ Division for Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo 0403, Norway. Electronic address: christine.ardal@fhi.no.
² Department of Engineering Sciences, Industrial Engineering and Management, Uppsala University, Uppsala, Sweden.
³ Department of Business Studies, Uppsala University, Uppsala, Sweden.
⁴ School of Law, Boston University, Boston, MA, USA; CARB-X, Boston, MA, USA.
⁵ CARB-X, Boston, MA, USA.
⁶ Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK.
⁷ GlaxoSmithKline, London, UK.

PMID: 28689703
DOI: 10.1016/S1473-3099(17)30404-8

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / biosynthesis
Anti-Bacterial Agents / chemical synthesis*
Anti-Bacterial Agents / pharmacology
Bacteria / drug effects
Bacteria / growth & development
Bacteria / pathogenicity
Congresses as Topic
Drug Industry / trends
Drug Resistance, Multiple, Bacterial*
Europe
Humans
International Cooperation / legislation & jurisprudence
Inventions / economics*
Inventions / trends
Public-Private Sector Partnerships / economics*
Public-Private Sector Partnerships / trends
Research / economics*
Research / trends

Substances

Anti-Bacterial Agents